• Amitriptyline HCl: Technical Guidance for Neuropharmacology

  2026-04-21

  Amitriptyline HCl (SKU B2231) is a high-purity tricyclic compound designed for precise neurotransmitter receptor modulation in neuropharmacology and mood disorder research. This product is best suited for in vitro and in vivo studies requiring stringent control over serotonin and norepinephrine receptor inhibition. It is not recommended where long-term solution stability or off-target mechanistic studies beyond its defined receptor profile are needed.

• Phillygenin Alleviates Diabetic Nephropathy via Key Inflamma

  2026-04-20

  This study demonstrates that phillygenin attenuates diabetic nephropathy by inhibiting inflammation and apoptosis through modulation of the TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β pathways. The findings reveal new therapeutic insights and highlight robust cell viability and signaling analyses as essential tools for DN research.

• Neurotensin: Precision Neurotensin Receptor 1 Activator for

  2026-04-20

  Neurotensin, a 13-amino acid neuropeptide, is redefining GPCR trafficking and miRNA modulation studies by offering high purity and reproducibility. Leveraging APExBIO’s validated Neurotensin (CAS 39379-15-2) enables advanced workflows in gastrointestinal and neural research, with robust strategies to overcome spectral interference and enhance data fidelity.

• Applied Workflows with 3-Deazaneplanocin (DZNep) in Cancer R

  2026-04-19

  3-Deazaneplanocin (DZNep) stands out as a versatile epigenetic modulator, enabling precise control over apoptosis and cell cycle regulation in diverse oncology and metabolic models. This article translates state-of-the-art research and best-practice protocols into actionable guidance, empowering researchers to overcome common pitfalls and maximize experimental reproducibility.

• ML-7 Hydrochloride: Precision MLCK Inhibitor for I/R Injury

  2026-04-18

  ML-7 hydrochloride offers robust, selective inhibition of myosin light chain kinase, enabling high-fidelity modeling of cardiac ischemia/reperfusion injury and endothelial dysfunction. This guide details advanced workflows, protocol parameters, and troubleshooting strategies for maximizing experimental reproducibility with ML-7 in cardiovascular research.

• Calpeptin: Advanced Calpain Inhibition for Fibrosis Pathway

  2026-04-17

  Explore how Calpeptin, a potent calpain inhibitor, enables precise dissection of fibrosis and inflammation mechanisms in pulmonary and cell death research. This article delivers new scientific insights, protocol guidance, and critical appraisal of calpain targeting strategies beyond existing resources.

• ATM Inhibition and Fenofibrate Synergy in Ovarian Cancer Cel

  2026-04-16

  This study demonstrates that ATM kinase inhibition, when combined with the PPARα agonist fenofibrate, synergistically induces senescence in high grade serous ovarian cancer (HGSOC) cells. The findings highlight metabolic remodeling as a promising therapeutic target for HR-proficient ovarian cancers, which are otherwise resistant to standard DNA repair-targeted therapies.

• HDAC Inhibition Reverses EBV-Induced Dedifferentiation in NP

  2026-04-15

  This study reveals how Epstein-Barr virus (EBV) latent protein LMP1 drives dedifferentiation and stem-like cellular plasticity in nasopharyngeal carcinoma (NPC) by suppressing CEBPA through HDAC1/2 recruitment. Notably, pharmacological HDAC inhibition restores differentiation, offering a mechanistic basis and therapeutic strategy for targeting plasticity in solid tumors.

• Tacalcitol monohydrate: Synthetic Vitamin D3 Analog for Rese

  2026-04-14

  Tacalcitol monohydrate is a synthetic analog of vitamin D3, acting via the vitamin D receptor to modulate gene expression in keratinocytes and cancer cells. It is validated for in vitro NGF induction and topical treatment for psoriasis vulgaris. The compound is a low-calcemic agent with robust mechanistic and translational research applications.

• Thrombin B Chain: Optimizing Fibrinogen to Fibrin Conversion

  2026-04-13

  Harness the precision of APExBIO's Coagulation Factor II (Thrombin) B Chain Fragment to model fibrin matrix formation, platelet activation, and advanced vascular biology. This guide delivers workflow enhancements, troubleshooting strategies, and practical insights for translational research in coagulation and angiogenesis.

• Tacrine Hydrochloride Hydrate: Mechanistic Leverage for Tran

  2026-04-13

  This thought-leadership article explores the mechanistic foundation and strategic deployment of Tacrine hydrochloride hydrate (Tetrahydroaminacrine) in cutting-edge Alzheimer's and neurodegenerative disease research. Integrating recent advances in cholinesterase inhibition, multi-target strategies, and workflow optimization, it provides translational researchers with actionable guidance, critical evidence, and a forward-looking vision—distinct from traditional product pages—while highlighting APExBIO's unique role in this evolving landscape.

• Ornithine Accumulation Drives CNS Toxicity via Liver–Brain A

  2026-04-12

  This study reveals how realgar-induced inhibition of hepatic OTC disrupts the urea cycle, causing ornithine accumulation that amplifies CNS toxicity through ZBTB7A-mediated suppression of astrocyte glycolysis. These findings clarify molecular crosstalk between the liver and brain in arsenic neurotoxicity and highlight potential targets for intervention.

• PR-619 in Precision DUB Inhibition: Protocols, Pitfalls & Pr

  2026-04-12

  Explore how PR-619, a broad-spectrum deubiquitylating enzymes inhibitor, transforms ubiquitination pathway research with uniquely practical and mechanistic insights. This article delivers advanced protocols, real-world troubleshooting, and a nuanced comparison to alternative methods.

• Perphenazine as a Dopamine D2 Antagonist: Applied Research W

  2026-04-11

  Perphenazine, a potent dopamine D2 receptor antagonist, is redefining both neuropharmacology and host-pathogen research. This article delivers actionable workflows, troubleshooting strategies, and data-driven insights for leveraging Perphenazine in cell death, immune modulation, and advanced translational studies.

• PR-619: Deubiquitylating Enzymes Inhibitor for Pathway Disse

  2026-04-11

  PR-619 stands apart as a broad-spectrum, reversible deubiquitylating enzymes inhibitor, enabling precise, proteasome-sparing manipulation of the ubiquitination pathway. Its robust cell permeability and compatibility with diverse assay modalities empower researchers in cancer biology, autophagy, and neurodegenerative disease models to interrogate protein homeostasis with unparalleled specificity.

15067 records 1/1005 page Next 12345 下5页 Last page